secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2025-04-07T23:59:59+00:00
Accession:  0001193125-25-073937
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian appoints Jeff Ajer to board; grants stock options to 14 new employees
------------------------------------------------------------------------------

- Jeff Ajer, former BioMarin CCO with 25+ years rare disease experience, appointed to VRDN board effective April 7, 2025.
- Ajer led launches of 5 brands at BioMarin; will support veligrotug BLA submission and potential commercial launch.
- Compensation Committee approved inducement grants of options for 220,750 shares to 14 new employees on April 1, 2025.
- Options vest over 4 years (25% at one-year anniversary, then monthly), exercise price equals closing price on grant date.
- Appointment strengthens board as Viridian advances veligrotug and FcRn portfolio toward regulatory milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525073937/0001193125-25-073937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525073937/d875125d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-073937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer